Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plasma Cell Disorder: early-phase trial registry
4 of 5 indexed Plasma Cell Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Plasma Cell Disorder: 5 US clinical trials tracked, 4 recruiting.
Plasma Cell Disorder is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Heidelberg Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition plasma-cell-disorder
OPEN 4 | RECR 80% | LATE 1 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Plasma Cell Disorder lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Plasma Cell Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Plasma Cell Disorder is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Plasma Cell Disorder research.
Heidelberg Pharma accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Plasma Cell Disorder trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Plasma Cell Disorder research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
NCT06870760
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Heidelberg Pharma
NCT04879043
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
University of Maryland, Baltimore
NCT07075510
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
University of Arkansas
NCT06313502
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
NCT03480360
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Plasma Cell Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Plasma Cell Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Plasma Cell Disorder page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Plasma Cell Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Heidelberg Pharma sponsors the most Plasma Cell Disorder trials on record, review their full trial history before evaluating a specific study. See Heidelberg Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plasma Cell Disorder condition card totals 5 registered trials; most-linked intervention cellcept; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.